孟鲁司特联合布地奈德治疗分泌性中耳炎的临床效果

Clinical effect of Montelukast combined with Budesonide in the treatment of secretory otitis media

目的探讨孟鲁司特联合布地奈德治疗分泌性中耳炎的临床效果。方法选取2018年1月至2021年1月湖南航天医院收治的142例分泌性中耳炎患者,按照随机数字表法分为对照组(71例)和观察组(71例)。两组患者均给予常规治疗,对照组患者加用布地奈德治疗,观察组在对照组的基础上加用孟鲁司特治疗。观察两组的临床疗效及鼓室压、语频气导听阈水平,比较两组的血清对氧磷酶-1(PON1)、脂氢过氧化物(LOOH)、转化生长因子-β;(TGF-β;)、转化生长因子-β;(TGF-β;)、血清白细胞介素-1β(IL-1β)、白细胞介素-8(IL-8)、降钙素原(PCT)及肿瘤坏死因子-α(TNF-α)水平。结果观察组的总有效率高于对照组,复发率低于对照组,差异有统计学意义(P<0.05);观察组治疗后的鼓室压及语频气导听阈水平低于对照组,差异有统计学意义(P<0.05);观察组治疗后的PON1水平高于对照组,LOOH水平低于对照组,差异有统计学意义(P<0.05);观察组治疗后的TGF-β;、TGF-β;水平均低于对照组,差异有统计学意义(P<0.05)。观察组治疗后的IL-1β、IL-8、PCT和TNF-α水平均低于对照组,差异有统计学意义(P<0.05)。结论采用孟鲁司特联合布地奈德治疗分泌性中耳炎可有效提高疗效,降低复发率,改善患者的症状及体征,同时提高了血清PON1水平,降低了LOOH及TGF-β;、TGF-β;水平,临床效果较好,值得推广应用。

Objective To explore the clinical effect of Montelukast combined with Budesonide in the treatment of secretory otitis media.Methods A total of 142 patients with secretory otitis media treated in Hu′nan Aerospace Hospital from January 2018 to January 2021 were selected,and they were divided into the control group(71 cases)and the observation group(71 cases)according to the random number table method.The patients in the two groups were given routine treatment,the patients in the control group were treated with Budesonide,and the patients in the observation group were treated with Montelukast on the basis of the control group.The clinical efficacy,tympanic pressure,speech frequency and air conduction hearing threshold of the two groups were observed,and the levels of serum paraoxonase-1(PON1),lipid hydroperoxide(LOOH)and transforming growth factor-β;(TGF-β;),transforming growth factor-β;(TGF-β;),serum interleukin-1β(IL-1β),interleukin-8(IL-8),procalcitonin(PCT)and tumor necrosis factor-α(TNF-α)were compared between the two groups.Results The total effective rate of the observation group was higher than that of the control group,and the recurrence rate of the observation group was lower than that of the control group,the differences were statistically significant(P<0.05).The tympanic pressure and speech frequency air conduction hearing threshold after treatment of the observation group were lower than those of the control group,the differences were statistically significant(P<0.05).The level of PON1 after treatment of the observation group was higher than that of the control group,and the level of LOOH after treatment of the observation group was lower than that of the control group,the differences were statistically significant(P<0.05).The levels of TGF-β;and TGF-β;after treatment in the observation group were lower than those in the control group,the differences were statistically significant(P<0.05).The levels of IL-1β,IL-8,PCT and TNF-αafter treatment in the observation group were lower than those in the control group,the differences were statistically significant(P<0.05).Conclusion Montelukast combined with Budesonide in the treatment of secretory otitis media can effectively improve its curative effect,reduce the recurrence rate,improve the symptoms and signs of patients,increase the level of serum PON1 and reduce the level of LOOH,TGF-β;and TGF-β;,the clinical effect is good,and it is worthy of popularization and application.